US Patent

US9636344 — Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts

Method of Use · Assigned to Bayer Intellectual Property GmbH · Expires 2032-03-29 · 6y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of a specific compound, 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride, for treating non-Hodgkin's lymphoma.

USPTO Abstract

The present invention relates to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof; and to its use for the treatment of non-Hodgkin's lymphoma.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2124`	—

Patent Metadata

Patent number: US9636344
Jurisdiction: US
Classification: Method of Use
Expires: 2032-03-29
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Intellectual Property GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.